| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 1999 American Heart Association, Inc.
Editorials |
The Immune System in Viral Myocarditis
Maintaining the Balance
From the Department of Medicine, University of California, San Diego, Calif.
Correspondence to Kirk U. Knowlton, MD, Department of Medicine, University of California, 9500 Gilman Dr, San Diego, CA 92093-0613C. E-mail kknowlton@ucsd.edu
Key Words: Coxsackievirus • myocarditis • cardiomyopathy • lymphocyte
 |
Introduction |
|---|
"Nature has provided in the white corpuscles as you call them—or the phagocytes as we call them—a natural means of devouring and destroying all disease germs. [However,] ...the inoculation that ought to cure sometimes kills."
Bernard Shaw, The Doctor's Dilemma, 1906
Dilated cardiomyopathy, one of the leading causes of heart failure in the United States, is a multifactorial disease that includes both hereditary and acquired forms.1 In patients, it has been shown that dilated cardiomyopathy can be a sequela of viral myocarditis.2 Although many different infectious agents have been attributed as the cause of viral myocarditis, enteroviruses, in particular Coxsackie B viruses, are consistently among the most common.2 The concept that enteroviruses contribute to the pathogenesis of a subset of human dilated cardiomyopathy has been strengthened by the detection of enteroviral genome in the hearts of patients with dilated cardiomyopathy. Since the first description by Bowles et al in 1986,3 many articles have addressed this issue (reviewed in Baboonian et al4 ). Although the results of individual studies vary, the data overall indicate that enteroviral genome is present in the heart of 15% to 25% of patients with dilated cardiomyopathy.4
Analogous to many other viral illnesses, both direct viral injury and
the immune response of the host play an important role in the
pathogenesis of viral heart disease. Furthermore, results from
experiments in murine models of viral myocarditis indicate that
although the immune response has an important protective role, it may
also have deleterious effects on the host. The
This article has been cited by other articles:
 |
|
 |
|
  J. C. Schultz, A. A. Hilliard, L. T. Cooper Jr, and C. S. Rihal Diagnosis and Treatment of Viral Myocarditis Mayo Clin. Proc., November 1, 2009; 84(11): 1001 - 1009. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Luo, J. Wong, and B. Wong Protein degradation systems in viral myocarditis leading to dilated cardiomyopathy Cardiovasc Res, August 6, 2009; (2009) cvp225v2. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. O. Weinzierl, D. Rudolf, D. Maurer, D. Wernet, H.-G. Rammensee, S. Stevanovic, and K. Klingel Identification of HLA-A*01- and HLA-A*02-restricted CD8+ T-cell epitopes shared among group B enteroviruses J. Gen. Virol., September 1, 2008; 89(9): 2090 - 2097. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Gao, J. Zhang, X. Si, J. Wong, C. Cheung, B. McManus, and H. Luo Proteasome inhibition attenuates coxsackievirus-induced myocardial damage in mice Am J Physiol Heart Circ Physiol, July 1, 2008; 295(1): H401 - H408. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Cheung, D. Marchant, E. K.-Y. Walker, Z. Luo, J. Zhang, B. Yanagawa, M. Rahmani, J. Cox, C. Overall, R. M. Senior, et al. Ablation of Matrix Metalloproteinase-9 Increases Severity of Viral Myocarditis in Mice Circulation, March 25, 2008; 117(12): 1574 - 1582. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Y. Gulbahar, W. C. Davis, T. Guvenc, M. Yarim, U. Parlak, and Y. B. Kabak Myocarditis Associated with Foot-and-Mouth Disease Virus Type O in Lambs Vet. Pathol., September 1, 2007; 44(5): 589 - 599. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Merl, C. Michaelis, B. Jaschke, M. Vorpahl, S. Seidl, and R. Wessely Targeting 2A Protease by RNA Interference Attenuates Coxsackieviral Cytopathogenicity and Promotes Survival in Highly Susceptible Mice Circulation, April 5, 2005; 111(13): 1583 - 1592. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-M. Kim, J.-H. Park, S.-K. Chung, J.-Y. Kim, H.-Y. Hwang, K.-C. Chung, I. Jo, S.-I. Park, and J.-H. Nam Coxsackievirus B3 Infection Induces cyr61 Activation via JNK To Mediate Cell Death J. Virol., December 15, 2004; 78(24): 13479 - 13488. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. DeBiasi, B. A. Robinson, B. Sherry, R. Bouchard, R. D. Brown, M. Rizeq, C. Long, and K. L. Tyler Caspase Inhibition Protects against Reovirus-Induced Myocardial Injury In Vitro and In Vivo J. Virol., October 15, 2004; 78(20): 11040 - 11050. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M G. Gagliardi, M Bevilacqua, C Bassano, B Leonardi, R Boldrini, F D. Camassei, A Fierabracci, A G Ugazio, and G F Bottazzo Long term follow up of children with myocarditis treated by immunosuppression and of children with dilated cardiomyopathy Heart, October 1, 2004; 90(10): 1167 - 1171. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. U. Knowlton and T. Yajima Interleukin-10: Biomarker or pathologic cytokine in fulminant myocarditis? J. Am. Coll. Cardiol., September 15, 2004; 44(6): 1298 - 1300. [Full Text] [PDF]
|
|
|
|
|
|
C. Kishimoto, Y. Hiraoka, N. Takamatsu, H. Takada, H. Kamiya, and H. Ochiai An in vivo model of autoimmune post-coxsackievirus B3 myocarditis in severe combined immunodeficiency mouse Cardiovasc Res, November 1, 2003; 60(2): 397 - 403. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Poller, H. Fechner, M. Noutsias, C. Tschoepe, M. Pauschinger, and H.-P. Schultheiss The molecular basis of cardiotropic viral infections Eur. Heart J. Suppl., December 1, 2002; 4(suppl_I): I18 - I30. [Abstract] [PDF]
|
|
|
|
 |
|
 H. M. Zhang, B. Yanagawa, P. Cheung, H. Luo, J. Yuan, D. Chau, A. Wang, L. Bohunek, J. E. Wilson, B. M. McManus, et al. Nip21 Gene Expression Reduces Coxsackievirus B3 Replication by Promoting Apoptotic Cell Death via a Mitochondria-Dependent Pathway Circ. Res., June 28, 2002; 90(12): 1251 - 1258. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Feuer, I. Mena, R. Pagarigan, M. K. Slifka, and J. L. Whitton Cell Cycle Status Affects Coxsackievirus Replication, Persistence, and Reactivation In Vitro J. Virol., March 27, 2002; 76(9): 4430 - 4440. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B.-K. Lim, S.-C. Choe, J.-O. Shin, S.-H. Ho, J.-M. Kim, S.-S. Yu, S. Kim, and E.-S. Jeon Local Expression of Interleukin-1 Receptor Antagonist by Plasmid DNA Improves Mortality and Decreases Myocardial Inflammation in Experimental Coxsackieviral Myocarditis Circulation, March 19, 2002; 105(11): 1278 - 1281. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. P. Liu and J. W. Mason Advances in the Understanding of Myocarditis Circulation, August 28, 2001; 104(9): 1076 - 1082. [Full Text] [PDF]
|
|
|
|
|
|
T. Peng, T. Sadusky, Y. Li, G. R. Coulton, H. Zhang, and L. C. Archard Altered expression of Bag-1 in Coxsackievirus B3 infected mouse heart Cardiovasc Res, April 1, 2001; 50(1): 46 - 55. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.M. Hare and K.L. Baughman Fulminant and acute lymphocytic myocarditis: the prognostic value of clinicopathological classification Eur. Heart J., February 2, 2001; 22(4): 269 - 270. [PDF]
|
|
|
|
 |
|
 M T Kearney, J M Cotton, P J Richardson, and A M Shah Viral myocarditis and dilated cardiomyopathy: mechanisms, manifestations, and management Postgrad. Med. J., January 1, 2001; 77(903): 4 - 10. [Abstract] [Full Text]
|
|
|
|
 |
|
 A. M. Feldman and D. McNamara Myocarditis N. Engl. J. Med., November 9, 2000; 343(19): 1388 - 1398. [Full Text] [PDF]
|
|
|
|
|
|
C. Badorff, B. Fichtlscherer, R. E. Rhoads, A. M. Zeiher, A. Muelsch, S. Dimmeler, and K. U. Knowlton Nitric Oxide Inhibits Dystrophin Proteolysis by Coxsackieviral Protease 2A Through S-Nitrosylation : A Protective Mechanism Against Enteroviral Cardiomyopathy Circulation, October 31, 2000; 102(18): 2276 - 2281. [Abstract] [Full Text] [PDF]
|
|